Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — H1 FY2016 Earnings Presentation
26 slides from Monash Ivf's earnings presentation, Feb 26, 2016
Slide 1: Monash IVF Group 1H16 Results Presentation
Monash IVF Group 1H16 Results Presentation 26 February 2016
Slide 2: Disclaimer
Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the date of this presentation. The information does not purpo
Slide 3: CEO Summary
CEO Summary 3 Monash IVF Group | Interim Financial Results Presentation 2016
Slide 4: Track record of strong financial performance
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Track record of strong financial performance Number of Patient Treatments¹ Revenue H2 H1 H2 H1 8,110 7,050 64.7 56.4 6,322 49.8 9,090 79.3 7,237 7,751 57.6 60.3 6,260 46.5 FY13 FY14 FY15 FY16 FY13 FY14 FY15 FY16 3 Year CAGR
Slide 5: 1H FY2016 Highlights
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary 1H FY2016 Highlights Revenues increased $19.0m (31.6%) to $79.3m vs pcp $79.3m $14.0m Ultrasound revenues grew >200% on pcp driven by the Revenue NPAT acquisition of Sydney Ultrasound for Women in June 2015 1H FY15 $60.
Slide 6: Australian IVF market movement
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Australian IVF market movement IVF Patient Treatment Growth Rates in Key Markets1 8.0% 7.6% We are experiencing a reversion to long term market trend growth rates Long Term Growth Rate of 4.1% Total MVF Key Market1 IVF Pa
Slide 7: Financial Highlights
Financial Highlights 7 Monash IVF Group | Interim Financial Results Presentation 2016
Slide 8: Profit and Loss analysis
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Profit and Loss analysis Revenues increased $19.0m (31.6%) $m 1H16 1H15 % change to $79.3m vs pcp including: Group revenues 79.3 60.3 31.6% 14.7% from organic growth EBITDA(1)(2) 24.5 19.3 26.8% 16.9% derived from acq
Slide 9: Revenue summary
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Revenue summary Revenue 1H16 vs 1H15 ($m) 1 Market growth: $2.5m increase against pcp due to Patient Treatment growth across VIC, QLD & NSW 5 3 4 2 2.0 Market share: Continued market share growth 0.3 across the MVF group 3
Slide 10: Segmental earnings
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Segmental earnings Revenue A$3.0m +$0.4m (15.4%) A$2.6m Australia Revenues increased by $18.6m (32.3%) to $76.3m vs pcp driven by: Market share growth in Key Markets and NSW 1H16 1H15 $79.3m $60.3m Reversion to trend
Slide 11: Cash flow highlights
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Cash flow highlights % $m 1H16 1H15 change Net operating cash flow 19.0 16.8 13.1% Cash flow from investing activities1 (4.3) (7.0) 38.6% Cash flow from financing activities (14.0) (13.4) (4.5%) Net cash flow movement 0.7 (
Slide 12: Capital Management
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Capital Management Balance Sheet ($m) Dec 15 Jun 15 % Net working capital position improved by $4.4m or change 30.1% Cash and cash equivalents 10.6 10.0 6.0% Net Debt reduced by $3.6m to $93.2m after $1.6m Other current
Slide 13: Operational Highlights
Operational Highlights 13 Monash IVF Group | Interim Financial Results Presentation 2016
Slide 14: Australian market share - IVF
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Australian market share - IVF % Market share - IVF 1H16 1H15 change Number of Monash Group IVF Patient 7,480 6,810 9.8% Treatments1 in Monash Group’s Key Markets2 Monash Group market share in Monash Group’s Key Markets2 – I
Slide 15: Pricing and treatment mix
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Pricing and treatment mix IVF Treatment numbers 1H16 1H15 % change IVF Cycles and Frozen Embryo Transfers Monash Group – Australia (FETs) patient treatment mix settled at 61.1% IVF Cycles1 5,229 4,421 18.3% Frozen embryo
Slide 16: Expanding domestic footprint
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Expanding domestic footprint Sydney Ultrasound For Women network (11 practices across Sydney, acquired June Acquisitions, New 2015). Integration with Monash Ultrasound for Women in advanced stages Locations & Monash IVF
Slide 17: International – KL Fertility
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary International – KL Fertility Continued strong growth in volumes achieved by new Fertility Specialists in the face of a challenging local economic climate EBITDA margin compression as these specialists gain traction and
Slide 18: Sydney Ultrasound for Women (SUFW)
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Sydney Ultrasound for Women (SUFW) Increased Group Revenues by 14.6% or $8.8m Delivered an EBITDA(1)(2) contribution of $2.0m with an EBITDA margin of 22.6% Ultrasound Scan volumes increased by 236.5% vs pcp Increas
Slide 19: FY16 Outlook
FY16 Outlook 19 Monash IVF Group | Interim Financial Results Presentation 2016
Slide 20: FY16 Full year outlook
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary FY16 Full year outlook As a result of our IVF Patient Treatment growth continuing in the first two months of 2H16 and the impact of the acquisitions into the Monash IVF Group in FY15, and subject to trading in the remaining
Slide 21: Strategy FY16 and beyond
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Strategy FY16 and beyond Our strategy remains consistent and focused, to profitably grow our business through leveraging our scientific capabilities across the clinic network Science, Continue to develop industry leading
Slide 22: Summary
Summary 22 Monash IVF Group | Interim Financial Results Presentation 2016
Slide 23: Summary
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Summary Track record of strong long term financial performance Delivered a strong performance in 1H16 with revenue growth (31.6%) and NPAT growth (27.6%) Acquisitions providing earnings growth in FY16 1H16 results i
Slide 24: Overview of Monash IVF Group
CEO Summary Financial Highlights Operational Highlights FY16 Outlook Summary Overview of Monash IVF Group Core Assisted Diagnostic and Ancillary Ultrasound Reproductive Services Services 22 clinics 2 specialised laboratories 17 clinics in Victoria and South 5 service centres Australia 16 S
Slide 25: Questions
Questions 25 Monash IVF Group | Interim Financial Results Presentation 2016
Slide 26: Monash IVF Group 1H16 Results Presentation
Monash IVF Group 1H16 Results Presentation 26 February 2016